Comparison of antisense oligonucleotide drug delivery systems

被引:45
|
作者
Weyermann, J
Lochmann, D
Zimmer, A
机构
[1] Karl Franzens Univ Graz, Dept Pharmaceut Technol, Inst Pharmaceut Sci, A-8010 Graz, Austria
[2] Univ Frankfurt, Inst Pharmaceut Technol, D-60439 Frankfurt, Germany
关键词
antisense oligonucleotide; nanoparticles; liposomes; protamine; proticles; polyoma; VPI; drug delivery systems; NMDA receptor;
D O I
10.1016/j.jconrel.2004.08.027
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Antisense oligonucleotides (AS-ONs) are specific drugs to inhibit gene expression at the transcriptional level. They possess a poor bioavailability and can be degraded by nucleases very rapidly. Therefore, a strong need for the development of oligonucleotide drug delivery systems exists. In the present study, two commercially available liposomes (DOTAP, lipofectin), one artificial virus capsoid (polyoma VP1), two cationic acrylate nanoparticles and two protamine-based nanoparticle preparations (proticles) were compared. Physical parameters of all carrier systems including z-average size, size distribution and surface charge regarding were determined. Cellular uptake was measured by a microplate fluorescence quantification method and, in addition, was visualized in mouse fibroblasts by confocal laser scan microscopy (CLSM). A comparison of cytotoxicity of the different drug delivery systems was performed in vitro using a MTT assay. Mouse fibroblasts which were stable transfected with the cDNA of a N-methyl-D-aspartate (NMDA) receptor also served as functional antisense oligonucleotide test system based on excitotoxicity (cell death). In addition, the efficiency of our oligonucleotide delivery systems was compared on the level of protein expression by Western blotting. Concluding the results, an increased uptake of the ON was found (2-18-fold) for all delivery systems compared to the free ON. Protamine-based nanoparticles showed a very low cytotoxicity in contradiction to all other carrier systems. Lipofectin could be identified as the most potent delivery system in terms of antisense effect, followed by protamine nanoparticles and DOTAP. Sequence-specific antisense effects up to 80% were observed in the functional cell death assay. The highest reduction of NMDA expression was obtained from liposomal preparations with approximately 60% analyzed by Western blot. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:411 / 423
页数:13
相关论文
共 50 条
  • [11] The macrophage as a Trojan horse for antisense oligonucleotide delivery
    Novak, James S.
    Jaiswal, Jyoti K.
    Partridge, Terence A.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2018, 22 (06) : 463 - 466
  • [12] Slow Release and Delivery of Antisense Oligonucleotide Drug by Self-Assembled Peptide Amphiphile Nanofibers
    Bulut, Selma
    Erkal, Turan S.
    Toksoz, Sila
    Tekinay, Ayse B.
    Tekinay, Turgay
    Guler, Mustafa O.
    BIOMACROMOLECULES, 2011, 12 (08) : 3007 - 3014
  • [13] Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics
    Ramasamy, Thiruganesh
    Ruttala, Hima Bindu
    Munusamy, Shankar
    Chakraborty, Nilay
    Kim, Jong Oh
    JOURNAL OF CONTROLLED RELEASE, 2022, 352 : 861 - 878
  • [14] Antisense oligonucleotide delivery into skin using in vivo electroporation
    Dokka, S
    Zhang, L
    Kelly, SA
    Hardee, GE
    MOLECULAR THERAPY, 2003, 7 (05) : S68 - S68
  • [15] Novel PLGA microspheres for sustained delivery of antisense oligonucleotide
    Jing Xie
    Xin Li
    Chao-jun Jiang
    Robert Jian-guang Lee
    Yu-lin Zhou
    Le-sheng Teng
    Chemical Research in Chinese Universities, 2013, 29 : 1003 - 1005
  • [16] Novel PLGA microspheres for sustained delivery of antisense oligonucleotide
    Xie Jing
    Li Xin
    Jiang Chao-jun
    Lee, Robert Jian-Guang
    Zhou Yu-lin
    Teng Le-sheng
    CHEMICAL RESEARCH IN CHINESE UNIVERSITIES, 2013, 29 (05) : 1003 - 1005
  • [17] Innovations in oligonucleotide drug delivery
    Lysik, MA
    Wu-Pong, S
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (08) : 1559 - 1573
  • [18] Topical delivery of antisense oligonucleotide using chitosan nanoparticles
    Ozbas-Turan, Suna
    Akbuga, Julide
    Sezer, Ali Demir
    HUMAN GENE THERAPY, 2008, 19 (10) : 1167 - 1167
  • [19] Advances in oligonucleotide drug delivery
    Roberts, Thomas C.
    Langer, Robert
    Wood, Matthew J. A.
    NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (10) : 673 - 694
  • [20] Advances in oligonucleotide drug delivery
    Thomas C. Roberts
    Robert Langer
    Matthew J. A. Wood
    Nature Reviews Drug Discovery, 2020, 19 : 673 - 694